GGHC
AKBA icon

Gilder Gagnon Howe & Co’s Akebia Therapeutics AKBA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-98,886
Closed -$1.28M – 237
2015
Q4 		$1.28M Buy
98,886
+65,153
+193% +$665K 0.02% 173
2015
Q3 		$326K Buy
+33,733
New +$310K 0.01% 219
2014
Q2 		– Sell
-62,380
Closed -$1.22M – 308
2014
Q1 		$1.22M Buy
+62,380
New +$1.31M 0.02% 208

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gilder Gagnon Howe & Co's AKBA Position: Q1 2016 in Review

Gilder Gagnon Howe & Co sold out of Akebia Therapeutics (AKBA) in Q1 2016, closing a stake of 98,886 shares — an estimated $1.28M sold.

Gilder Gagnon Howe & Co first reported a position in AKBA in Q1 2014 and held it in 3 quarters. The position peaked at $1.28M in Q4 2015. 91 funds tracked by Wall St. Rank hold AKBA as of Q1 2016.

  • Gilder Gagnon Howe & Co reported no remaining Akebia Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 98,886 Akebia Therapeutics shares in Q1 2016, an estimated $1.28M.
  • Gilder Gagnon Howe & Co first reported a position in Akebia Therapeutics in Q1 2014 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Akebia Therapeutics position peaked at $1.28M in Q4 2015.
  • 91 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2016, filed 3 May 2016.